论文信息 - Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET) - 字舞流文

Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET)

Y. Bang | E. Raymond | A. Vinik | H. Kennecke | J. Picus | P. Metrakos | C. Lombard-Bohas | P. Niccoli | D. Castellano | J. Valle | J. Raoul | I. Borbath | R. Chao | E. Cutsem | Denis Smith | G. Hazel | D. Lu | D. Hoersch | S. Patyna | J. Chen